December 06, 2024

Scientists Receives ERC Consolidator Grant – Funding for the Central Institute of Mental Health

Scientists Receives ERC Consolidator Grant – Funding for the Central Institute of Mental Health

An ERC Consolidator Grant will go to PD Dr Gordon Feld, who does research into sleep and memory at the Central Institute of Mental Health in Mannheim and teaches at Ruperto Carola’s Institute of Psychology.

PD Dr Gordon Feld | © Daniel Lukac/ZI

Dr Feld’s project, entitled “Tracking Memory During Sleep: Understanding How Replay of Complex Information Affects Memory and Mental Health” (MemoryTracker), is about how memories are processed during sleep and their potential capacity for treating mental disorders. His research focuses on discovering how current research findings can be transferred – inter alia with the aid of modern neuroscientific methods – into practical psychotherapeutic options. The European Research Council has allocated approximately two million euros to fund the studies over five years. Since 2019, Gordon Feld has headed the Emmy Noether Group “Psychology and Neurobiology of Sleep and Memory”, which is located in the Department Clinical Psychology at the Central Institute of Mental Health. The researcher also teaches at Heidelberg University’s Institute of Psychology.

The European Research Council awards the ERC Consolidator Grant to outstanding researchers with the aim of consolidating their academic independence. The central criterion for funding is scientific excellence.

Our latest News

discover more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp